27812586|t|Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate
27812586|a|Herein, we report a new process that enables the gram-scale production of a fully synthetic anti-cancer vaccine for human use. This therapeutic vaccine candidate, named MAG-Tn3, is a high-molecular-weight tetrameric glycopeptide encompassing carbohydrate tumor-associated Tn antigen clusters and peptidic CD4(+) T-cell epitopes. The synthetic process involves (i) the stepwise solid-phase assembly of protected amino acids, including the high value-added Tn building blocks with only 1.5 equivalents, (ii) a single isolated intermediate, and (iii) the simultaneous deprotection of 36 hindered protective groups. The resulting MAG-Tn3 was unambiguously characterized using a combination of techniques, including a structural analysis by nuclear magnetic resonance spectroscopy. The four peptidic chains are flexible in solution, with a more constrained but extended conformation at the Tn3 antigen motif. Finally, we demonstrate that, when injected into HLA-DR1 - expressing transgenic mice, this vaccine induces Tn-specific antibodies that mediate the killing of human Tn-positive tumor cells. These studies led to a clinical batch of the MAG-Tn3, currently investigated in breast cancer patients (phase I clinical trial). The current study demonstrates the feasibility of the multigram-scale synthesis of a highly pure complex glycopeptide, and it opens new avenues for the use of synthetic glycopeptides as drugs in humans.
27812586	0	11	Large-scale	T081	C0392762
27812586	12	21	synthesis	T052	C1883254
27812586	26	36	structural	T085	C0026383
27812586	37	45	analysis	T169	C1524024
27812586	51	60	synthetic	T052	C1883254
27812586	61	73	glycopeptide	T116	C0017953
27812586	74	83	dendrimer	T104,T122	C1563732
27812586	90	109	anti-cancer vaccine	T116,T121,T129	C0376659
27812586	140	143	new	T080	C0205314
27812586	144	151	process	T169	C1519894
27812586	169	179	gram-scale	T081	C0392762
27812586	180	190	production	T057	C0033268
27812586	202	211	synthetic	T052	C1883254
27812586	212	231	anti-cancer vaccine	T116,T121,T129	C0376659
27812586	236	241	human	T016	C0086418
27812586	252	271	therapeutic vaccine	T116,T121,T129	C0301521
27812586	289	296	MAG-Tn3	T121	C1254351
27812586	303	324	high-molecular-weight	T080	C1979900
27812586	325	348	tetrameric glycopeptide	T116	C0017953
27812586	362	402	carbohydrate tumor-associated Tn antigen	T109,T129	C0003341
27812586	403	411	clusters	T081	C1704332
27812586	416	424	peptidic	T116	C0030956
27812586	425	438	CD4(+) T-cell	T025	C0039215
27812586	439	447	epitopes	T129	C0003316
27812586	453	470	synthetic process	T052	C1883254
27812586	497	517	solid-phase assembly	T052	C0441655
27812586	521	530	protected	T080	C0205556
27812586	531	542	amino acids	T116,T121,T123	C0002520
27812586	575	577	Tn	T109,T129	C0076765
27812586	578	593	building blocks	T080	C0205556
27812586	635	643	isolated	T169	C0205409
27812586	644	656	intermediate	T167	C0439861
27812586	672	684	simultaneous	T079	C0521115
27812586	685	697	deprotection	T070	C2350458
27812586	713	730	protective groups	T120	C0597294
27812586	746	753	MAG-Tn3	T121	C1254351
27812586	772	785	characterized	T052	C1880022
27812586	794	805	combination	T080	C0205195
27812586	809	819	techniques	T169	C0449851
27812586	833	843	structural	T085	C0026383
27812586	844	852	analysis	T169	C1524024
27812586	856	895	nuclear magnetic resonance spectroscopy	T060	C0877853
27812586	906	914	peptidic	T116	C0030956
27812586	926	934	flexible	T080	C0443220
27812586	960	971	constrained	T077	C1707494
27812586	985	997	conformation	T082	C1518960
27812586	1005	1016	Tn3 antigen	T109,T129	C0076765
27812586	1073	1080	HLA-DR1	T129	C0019768
27812586	1083	1093	expressing	T045	C1171362
27812586	1094	1109	transgenic mice	T015	C0025936
27812586	1116	1123	vaccine	T116,T121,T129	C0376659
27812586	1124	1131	induces	T169	C0205263
27812586	1132	1154	Tn-specific antibodies	T116,T129	C0003241
27812586	1172	1179	killing	T043	C0599733
27812586	1183	1188	human	T016	C0086418
27812586	1189	1212	Tn-positive tumor cells	T025	C0431085
27812586	1259	1266	MAG-Tn3	T121	C1254351
27812586	1278	1290	investigated	T169	C1292732
27812586	1294	1307	breast cancer	T191	C0006142
27812586	1308	1316	patients	T101	C0030705
27812586	1318	1340	phase I clinical trial	T062	C0282459
27812586	1397	1412	multigram-scale	T081	C0392762
27812586	1413	1422	synthesis	T052	C1883254
27812586	1428	1434	highly	T080	C0205250
27812586	1435	1439	pure	T080	C0205556
27812586	1440	1447	complex	T104	C1704241
27812586	1448	1460	glycopeptide	T116	C0017953
27812586	1475	1478	new	T080	C0205314
27812586	1502	1511	synthetic	T052	C1883254
27812586	1512	1525	glycopeptides	T116	C0017953
27812586	1529	1534	drugs	T121	C0013227
27812586	1538	1544	humans	T016	C0086418